By Fineline Cube GlaxoSmithKline (GSK, NYSE: GSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300 million upfront to GSK, with $100 million FDA approval milestone anticipated pre-close (PDUFA date: March 24, 2026), and up to $690 million total value including regulatory, sales milestones, and tiered double-digit royalties.
Transaction Structure
| Component | Value | Trigger |
|---|---|---|
| Upfront Payment | $300 million | Signing |
| FDA Approval Milestone | $100 million | U.S. approval (expected pre-close; PDUFA March 24, 2026) |
| EU/UK Approval Milestone | $20 million | Regulatory clearance |
| Sales-Based Milestones | Up to $270 million | Revenue thresholds |
| Royalties | Tiered double-digit | Net global sales |
| Total Potential Value | ~$690 million | — |
Drug Profile & Mechanism
| Attribute | Linerixibat Specification |
|---|---|
| Drug Class | Ileal bile acid transporter (IBAT) inhibitor |
| Target | IBAT (apical sodium-dependent bile acid transporter) |
| Mechanism | Blocks bile acid reuptake in terminal ileum → reduces circulating bile acid load |
| Clinical Effect | Reduces multiple pruritus mediators → alleviates cholestatic itch |
| Indication | Cholestatic pruritus associated with primary biliary cholangitis (PBC) |
| Route | Oral, targeted therapy |
| Unmet Need | Debilitating pruritus in ~60% of PBC patients; inadequate response to ursodeoxycholic acid (UDCA) |
Strategic Rationale
GSK Objectives:
- Portfolio Optimization: Divest non-core rare disease asset; focus resources on vaccines, infectious disease, respiratory
- Value Realization: Monetize Phase III-ready program near regulatory inflection point
- Risk Transfer: Alfasigma assumes commercial execution, manufacturing scale-up
Alfasigma Strategy:
- Rare Disease Expansion: Entry into hepatology/cholestatic disease; complements GI portfolio
- Global Commercial Infrastructure: Leverage European strength (Italy-based) for PBC pruritus market development
- Near-Term Revenue: FDA approval anticipated weeks post-deal; immediate U.S. launch capability
Market Context & Competitive Landscape
| Factor | Market Implication |
|---|---|
| PBC Prevalence | ~130,000 diagnosed U.S. patients; 65% experience moderate-severe pruritus |
| Standard of Care | UDCA first-line; ~40% inadequate response; pruritus often refractory |
| Competitive Threats | Gilead’s seladelpar (PPARδ agonist) approved 2024; obeticholic acid (OCALIVA) delisted from China; IBAT class emerging |
| IBAT Class | Linerixibat first-to-market potential; maralixibat (Mirum) approved for Alagille syndrome pruritus (pediatric) |
| Pricing Power | Orphan indication supports premium pricing; U.S. annual cost anticipated $50,000-75,000 |
Regulatory Timeline & Launch Outlook
| Milestone | Date | Status |
|---|---|---|
| PDUFA Target | March 24, 2026 | FDA decision pending |
| Deal Close | Post-FDA approval | Alfasigma assumes global rights |
| EU Filing | 2026 | MAA submission anticipated |
| Commercial Launch | Q2 2026 (U.S.) | Alfasigma U.S. infrastructure activation |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding FDA approval timelines, commercial launch execution, and sales milestone achievement for linerixibat. Actual results may differ due to regulatory decisions, competitive dynamics with PPAR agonists, and pricing negotiations.-Fineline Info & Tech